The PFA-100® detects sub-optimal antiplatelet responses in patients on aspirin

Reference

• Roth G J, Calverley D C. Aspirin, platelets, and thrombosis - theory and practice. Blood 1994; 83: 885–898.
   PubMed Web of Science ®Google Scholar
• Willard J E, Lange R A, Hills L D. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175–181.
   PubMed Web of Science ®Google Scholar
• Fuster V, Dyken M L, Vokonas P S, Hennekens Ch. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993; 87: 559–675.
   Web of Science ®Google Scholar
• Grotemeyer K H, Scharafinski H W, Husstedt I W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71:397–403.
   PubMed Web of Science ®Google Scholar
• Helgason C M, Bolin K M, Hoff J A, Winkler S R, Mangat A, Tortorice K L et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331–2336.
   PubMed Web of Science ®Google Scholar
• Buchanan M R, Brister S J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 221–227.
   PubMed Web of Science ®Google Scholar
• Kundu S K, Heilmann E J, Sio R, Garcia C, Davidson R M, Ostgaard R A. Description of an in vitro platelet funct- ion analyzer - PFA- 100TM. Seminars in Thrombosis and Hemostasis 1995; 21: 106–112.
   Google Scholar
• Marshall P W, Williams A J, Dixon R M, Growcott J W, Warburton S, Armstrong J, et al. A comparison of the effects of aspirin on bleeding time measured using the SimplateTM method and closure time measured using the PFA-100(TM), in healthy volunteers. British Journal of Clinical Pharmacology 1997; 44: 151–155.
   PubMed Web of Science ®Google Scholar
• Mammen E F, Comp P C, Gosselin R, Greenberg C, Hoots W K, Kessler C M, et al. PFA-100 TM system: A new method for assessment of platelet dysfunction. Seminars in Thrombosis and Hemostasis 1998; 24: 195–202.
   Google Scholar
• Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100(R). Thromb Haemost 2000; 83: 316–321.
   PubMed Web of Science ®Google Scholar
• Feuring M, Haseroth K, Janson C P, Falkenstein E, Schmidt B W, Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100). International Journal of Clinical Pharmacology and Therapeutics 1999; 37: 584–588.
   Google Scholar
• McKenzie M E, Gurbel P A, Levine D J, Serebruany V L. Clinical utility of available methods for determining platelet function. Cardiology 1999; 92: 240–247.
   PubMed Web of Science ®Google Scholar
• Hezard N, Metz D, Nazeyrollas P, Droulle C, Elaerts J, Potron G, et al. Use ct the PFA-100 (TM) apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000; 83: 540–544.
   PubMed Web of Science ®Google Scholar
• Lasne D, Fiemeyer A, Chatellier G, Chammas C, Baron J F. A study of platelet functions with a new analyzer using high shear stress (PFA 100) in patients undergoing coronary artery bypass graft. Thromb Haemost 2000; 84: 794–799.
   PubMed Web of Science ®Google Scholar
• Madan M, Berkowitz S D, Christie D J, Jennings L K, Smit A C, Sigmon K N, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer PFA-100 during percutaneous coronary intervention. American Heart Journal 2001; 141: 226–233.
   Google Scholar
• Serebruany V L, Alford A B, Meister A F, Fuzaylov S Y, Gattis W A, Gurbel P A, et al. Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). Thromb Res 2001; 101: 427–433.
   PubMed Web of Science ®Google Scholar
• Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA 100TM): Influence of hematocrit elevation. Haematologica 1999; 84: 614–619.
   PubMed Web of Science ®Google Scholar
• Chamorro A, Escolar G, Revilla M, Obach V, Vila N, Reverter J C, et al. 1999. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. Journal of the Neurological Sciences 171: 110–114.
   PubMed Web of Science ®Google Scholar
• Ciabattoni G, Maclouf J, Catella F, FitzGerald G A, Patrono C. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 293–297.
   Google Scholar
• Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thrombosis Research 2002; 108: 37–42.
   PubMed Web of Science ®Google Scholar
• Gum P A, Kottke-Marchant K, Poggio E D, Gurm H, Welsh P A, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230–235.
   PubMed Web of Science ®Google Scholar
• Grotemeyer K H. Effects of Acetylsalicyclic Acid in Stroke Patients Evidence of Nonresponders in A Subpopulation of Treated Patients. Thrombosis Research 1991; 63: 587–593.
   PubMed Web of Science ®Google Scholar
• Helgason C M, Tortorice K L, Winkler S R, Penney D W, Schuler J J, McClelland T J, et al. Aspirin Response and Failure in Cerebral Infarction. Stroke 1993; 24: 345–350.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative metaa- nalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71–86.
   PubMed Web of Science ®Google Scholar
• Lopez-Farre A, Caramelo C, Esteban A, Alberola M L, Millas I, Monton M, et al. Effects of aspirin on platelet-neutrophil interactions: Role of nitric oxide and endothelin-1. Circulation 1995; 91: 2080–2088.
   PubMed Web of Science ®Google Scholar
• Valles J, Santos M T, Aznar J, Osa A, Lago A, Cosin J et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effectsof erythrocytes on platelet reactivity. Circulation 1998; 97:350–355.
   PubMed Web of Science ®Google Scholar
• Eikelboom J W, Hirsh J, Weitz J L, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–1655.
   Google Scholar
• Pratico D, Cyrus T, Li H, FitzGerald G A. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000; 96: 3823–3826.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23: 1400–1403.
   PubMed Web of Science ®Google Scholar
• Gawaz M, Neumann F J, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease. Circulation 1999; 99: E1–E11.
   PubMed Web of Science ®Google Scholar
• Trip M D, Cats V M, van Capelle F J, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549–1554.
   PubMed Web of Science ®Google Scholar